ARO-ANG3 + sterile normal saline (0.9% NaCl)
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dyslipidemias
Conditions
Dyslipidemias, Familial Hypercholesterolemia, Hypertriglyceridemia
Trial Timeline
Jan 7, 2019 → May 17, 2021
NCT ID
NCT03747224About ARO-ANG3 + sterile normal saline (0.9% NaCl)
ARO-ANG3 + sterile normal saline (0.9% NaCl) is a phase 1 stage product being developed by Arrowhead Pharmaceuticals for Dyslipidemias. The current trial status is completed. This product is registered under clinical trial identifier NCT03747224. Target conditions include Dyslipidemias, Familial Hypercholesterolemia, Hypertriglyceridemia.
What happened to similar drugs?
6 of 6 similar drugs in Dyslipidemias were approved
Approved (6) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03747224 | Phase 1 | Completed |
Competing Products
15 competing products in Dyslipidemias
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY3202328 + Placebo + Atorvastatin + Simvastatin | Eli Lilly | Phase 1 | 29 |
| Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mg | Yuhan | Approved | 43 |
| LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SC | Eli Lilly | Phase 1 | 29 |
| LY3885125 + Placebo | Eli Lilly | Phase 1 | 21 |
| LY3561774 + Placebo | Eli Lilly | Phase 1 | 29 |
| LY3561774 + Placebo | Eli Lilly | Phase 2 | 35 |
| LY2484595 + Placebo + Atorvastatin | Eli Lilly | Phase 2 | 35 |
| Atorvastatin + Atorvastatin | Pfizer | Approved | 43 |
| Atorvastatin | Pfizer | Approved | 43 |
| Atorvastatin + Atorvastatin + Atorvastatin | Pfizer | Approved | 43 |
| Vupanorsen + Placebo | Pfizer | Phase 2 | 35 |
| Atorvastatin | Pfizer | Approved | 43 |
| Atorvastatin + Atorvastatin + Atorvastatin | Pfizer | Approved | 43 |
| GWP42003 + GWP42003 + GWP42004 + Placebo | Jazz Pharmaceuticals | Phase 2 | 32 |
| ARO-APOC3 | Arrowhead Pharmaceuticals | Phase 2 | 32 |